Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887280831> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2887280831 endingPage "e869" @default.
- W2887280831 startingPage "e865" @default.
- W2887280831 abstract "We exhibit our ongoing multicenter, prospective, single-arm, phase II trial of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor (PEG-G-CSF) support for chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (NSCLC) (University Hospital Medical Information Network database: UMIN000030598). Docetaxel monotherapy is the Japanese standard of care for chemotherapy-naive elderly patients with advanced NSCLC. Docetaxel plus ramucirumab showed superior survival benefit over docetaxel monotherapy in the second-line setting for NSCLC. A Japanese phase II study comparing docetaxel plus ramucirumab and docetaxel monotherapy in the second-line setting showed febrile neutropenia (FN) incidence of approximately one-third in the docetaxel plus ramucirumab arm. Docetaxel plus ramucirumab could be a promising candidate for elderly patients with NSCLC, but such high FN incidence is a clinically critical concern. To overcome this problem, we adopt a routine primary prophylactic PEG-G-CSF with docetaxel plus ramucirumab therapy. We hypothesize that primary prophylactic PEG-G-CSF reduces FN and maximizes the efficacy of docetaxel plus ramucirumab in Japanese elderly patients with NSCLC. Intravenous docetaxel (60 mg/m2, day 1) plus ramucirumab (10 mg/kg, day 1) with subcutaneous PEG-G-CSF (3.6 mg, day 2) every 3 weeks is administered until progression. The primary endpoint is overall response rate (ORR). We decided the threshold ORR to be 20%, and the expected ORR 35%. Taking statistical points (α/β errors: 0.05/0.80) and ineligible patients into account, the sample size was set at 65. When the study results are promising, we will conduct a phase III trial to compare docetaxel plus ramucirumab with PEG-G-CSF support versus docetaxel monotherapy for chemotherapy-naive elderly patients with NSCLC." @default.
- W2887280831 created "2018-08-22" @default.
- W2887280831 creator A5017789799 @default.
- W2887280831 creator A5022022857 @default.
- W2887280831 creator A5024261346 @default.
- W2887280831 creator A5032337115 @default.
- W2887280831 creator A5080938148 @default.
- W2887280831 creator A5081110935 @default.
- W2887280831 date "2018-11-01" @default.
- W2887280831 modified "2023-09-27" @default.
- W2887280831 title "Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non–small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L)" @default.
- W2887280831 cites W2000487326 @default.
- W2887280831 cites W2119038990 @default.
- W2887280831 cites W2121095198 @default.
- W2887280831 cites W2137009016 @default.
- W2887280831 cites W2140980839 @default.
- W2887280831 cites W2142195688 @default.
- W2887280831 cites W2145238269 @default.
- W2887280831 cites W2153297361 @default.
- W2887280831 cites W2503271931 @default.
- W2887280831 cites W2607182122 @default.
- W2887280831 doi "https://doi.org/10.1016/j.cllc.2018.07.009" @default.
- W2887280831 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30206044" @default.
- W2887280831 hasPublicationYear "2018" @default.
- W2887280831 type Work @default.
- W2887280831 sameAs 2887280831 @default.
- W2887280831 citedByCount "3" @default.
- W2887280831 countsByYear W28872808312019 @default.
- W2887280831 countsByYear W28872808312020 @default.
- W2887280831 crossrefType "journal-article" @default.
- W2887280831 hasAuthorship W2887280831A5017789799 @default.
- W2887280831 hasAuthorship W2887280831A5022022857 @default.
- W2887280831 hasAuthorship W2887280831A5024261346 @default.
- W2887280831 hasAuthorship W2887280831A5032337115 @default.
- W2887280831 hasAuthorship W2887280831A5080938148 @default.
- W2887280831 hasAuthorship W2887280831A5081110935 @default.
- W2887280831 hasBestOaLocation W28872808311 @default.
- W2887280831 hasConcept C121608353 @default.
- W2887280831 hasConcept C126322002 @default.
- W2887280831 hasConcept C143998085 @default.
- W2887280831 hasConcept C203092338 @default.
- W2887280831 hasConcept C2775999482 @default.
- W2887280831 hasConcept C2776256026 @default.
- W2887280831 hasConcept C2776694085 @default.
- W2887280831 hasConcept C2777063308 @default.
- W2887280831 hasConcept C2777626846 @default.
- W2887280831 hasConcept C2778850193 @default.
- W2887280831 hasConcept C2779551604 @default.
- W2887280831 hasConcept C2781182431 @default.
- W2887280831 hasConcept C2781190966 @default.
- W2887280831 hasConcept C31760486 @default.
- W2887280831 hasConcept C535046627 @default.
- W2887280831 hasConcept C71924100 @default.
- W2887280831 hasConceptScore W2887280831C121608353 @default.
- W2887280831 hasConceptScore W2887280831C126322002 @default.
- W2887280831 hasConceptScore W2887280831C143998085 @default.
- W2887280831 hasConceptScore W2887280831C203092338 @default.
- W2887280831 hasConceptScore W2887280831C2775999482 @default.
- W2887280831 hasConceptScore W2887280831C2776256026 @default.
- W2887280831 hasConceptScore W2887280831C2776694085 @default.
- W2887280831 hasConceptScore W2887280831C2777063308 @default.
- W2887280831 hasConceptScore W2887280831C2777626846 @default.
- W2887280831 hasConceptScore W2887280831C2778850193 @default.
- W2887280831 hasConceptScore W2887280831C2779551604 @default.
- W2887280831 hasConceptScore W2887280831C2781182431 @default.
- W2887280831 hasConceptScore W2887280831C2781190966 @default.
- W2887280831 hasConceptScore W2887280831C31760486 @default.
- W2887280831 hasConceptScore W2887280831C535046627 @default.
- W2887280831 hasConceptScore W2887280831C71924100 @default.
- W2887280831 hasFunder F4320333624 @default.
- W2887280831 hasIssue "6" @default.
- W2887280831 hasLocation W28872808311 @default.
- W2887280831 hasLocation W28872808312 @default.
- W2887280831 hasOpenAccess W2887280831 @default.
- W2887280831 hasPrimaryLocation W28872808311 @default.
- W2887280831 hasRelatedWork W1951833431 @default.
- W2887280831 hasRelatedWork W2149964424 @default.
- W2887280831 hasRelatedWork W2168103287 @default.
- W2887280831 hasRelatedWork W2289652418 @default.
- W2887280831 hasRelatedWork W2571248030 @default.
- W2887280831 hasRelatedWork W2649565258 @default.
- W2887280831 hasRelatedWork W2887280831 @default.
- W2887280831 hasRelatedWork W3001437527 @default.
- W2887280831 hasRelatedWork W3199137677 @default.
- W2887280831 hasRelatedWork W4225344194 @default.
- W2887280831 hasVolume "19" @default.
- W2887280831 isParatext "false" @default.
- W2887280831 isRetracted "false" @default.
- W2887280831 magId "2887280831" @default.
- W2887280831 workType "article" @default.